Camp4 Therapeutics Corp
Business
Camp4 Therapeutics is a clinical-stage biopharmaceutical company developing RNA-targeting therapeutics to upregulate gene expression and treat genetic diseases. The company's lead candidate, CMP-002, is an intrathecally delivered antisense oligonucleotide designed to increase SYNGAP1 protein levels for SYNGAP1-related disorder, with a Phase 1/2 trial planned for H2 2026. Camp4 also has CMP-001 in clinical development for urea cycle disorders and discovery programs in other CNS indications, leveraging its proprietary RAP Platform to identify regulatory RNAs and develop ASO therapeutics. The company operates through research partnerships, including a GSK collaboration agreement, and relies on third-party contract manufacturers.
Summary from 10-K filed 2026-03-05
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Research and collaboration revenue | 3 | 652,000 | 350,000 | |
| Research and development | 38 | 39 | 41 | |
| General and administrative | 17 | 15 | 12 | |
| Impairment of right-of-use asset | 494,000 | 0 | — | |
| Total operating expenses | 56 | 54 | 52 | |
| Loss from operations | −53 | −53 | −52 | |
| Interest income | 2 | 1 | 3 | |
| Change in fair value of derivative tranche liability | −30 | 0 | — | |
| Other expense | −192,000 | −33,000 | −220,000 | |
| Total other (expense) income, net | −28 | 1 | 3 | |
| Net loss | −80 | −52 | −49 | |
| Net loss per share attributable to common stockholders, basic, (in USD per share) | −2.65 | −11.04 | −124.8 | |
| Net loss per share attributable to common stockholders, diluted, (in USD per share) | −2.65 | −11.04 | −124.8 | |
| Weighted-average shares of common stock outstanding, basic, (in shares) | 30 | 5 | 394,976 | |
| Weighted-average shares of common stock outstanding, diluted, (in shares) | 30 | 5 | 394,976 | |
| Other comprehensive income (loss) | 0 | 0 | — | |
| Total comprehensive loss | −80 | −52 | −49 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 110 | 64 | 38 | — | |
| Restricted cash, current portion | 1 | 0 | — | — | |
| Prepaid expenses and other current assets | 3 | 2 | 2 | — | |
| Total current assets | 114 | 66 | 40 | — | |
| Restricted cash, net of current portion | 894,000 | 2 | 2 | — | |
| Property and equipment, net | 2 | 4 | — | — | |
| Operating lease right-of-use assets | 397,000 | 6 | 8 | — | |
| Other assets | 83,000 | 427,000 | — | — | |
| Total assets | 118 | 78 | 55 | — | |
| Accounts payable | 182,000 | 1 | 1 | — | |
| Accrued expenses and other current liabilities | 6 | 5 | 3 | — | |
| Current portion of deferred revenue | 9 | 385,000 | 0 | — | |
| Operating lease liabilities, current portion | 286,000 | 3 | 3 | — | |
| Other current liabilities | 27,000 | 176,000 | — | — | |
| Total current liabilities | 16 | 10 | 8 | — | |
| Deferred revenue, net of current portion | 8 | 0 | — | — | |
| Operating lease liabilities, net of current portion | 2 | 5 | 8 | — | |
| Derivative tranche liability | 45 | 0 | — | — | |
| Other liabilities | 29,000 | 72,000 | 2,000 | — | |
| Total liabilities | 70 | 15 | 17 | — | |
| Commitments and contingencies (Note 7) | — | — | — | — | |
| Common stock, $0.0001 par value per share; 175,000,000 shares authorized as of December 31, 2025 and 2024; 51,902,614 issued and outstanding as of December 31, 2025; 20,161,073 and 20,145,129 shares issued and outstanding as of and December 31, 2024, respectively | 6,000 | 2,000 | 1,000 | — | |
| Additional paid-in capital | 340 | 275 | 36 | — | |
| Accumulated deficit | −292 | −212 | −160 | — | |
| Total stockholders equity | 48 | 63 | −124 | −78 | |
| Total liabilities and stockholders equity | 118 | 78 | 55 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Depreciation and amortization | 2 | 2 | 2 | |
| Stock-based compensation expense | 4 | 4 | 3 | |
| Loss on the sale of property and equipment | 258,000 | 0 | — | |
| Non-cash gain on lease modification | −316,000 | 0 | — | |
| Non-cash lease expense | 2 | 2 | — | |
| Non-cash interest expense | 16,000 | 83,000 | 92,000 | |
| Prepaid expenses and other current assets | −888,000 | −711,000 | −420,000 | |
| Accounts payable | −1 | 168,000 | −1 | |
| Accrued expenses and other liabilities | 805,000 | 2 | −136,000 | |
| Operating lease assets and liabilities | −3 | −3 | 402,000 | |
| Deferred revenue | 17 | 385,000 | 0 | |
| Net cash used in operating activities | −30 | −46 | −44 | |
| Purchases of property and equipment | −279,000 | −441,000 | −678,000 | |
| Proceeds from the sale of property and equipment | 36,000 | 0 | — | |
| Net cash used in investing activities | −243,000 | −441,000 | −678,000 | |
| Proceeds from issuance of common stock, net of issuance costs of $3,966 and $5,747, respectively | 58 | 76 | 0 | |
| Proceeds from issuance of pre-funded warrants, net of issuance costs $258 | 4 | 0 | — | |
| Proceeds allocated to the derivative tranche liability | 15 | 0 | — | |
| Proceeds from exercise of common stock options | 51,000 | 113,000 | 700,000 | |
| Principal payments on financing obligation | −97,000 | −460,000 | −268,000 | |
| Principal payments on finance leases | −111,000 | −364,000 | −322,000 | |
| Payments of deferred issuance costs | 0 | −4 | — | |
| Net cash provided by financing activities | 76 | 72 | 301,000 | |
| Net increase in cash, cash equivalents and restricted cash | 46 | 26 | −45 | |
| Conversion of convertible preferred stock upon initial public offering | 0 | 162 | 0 | |
| Finance lease right-of-use asset converted to fixed asset | 290,000 | 127,000 | 0 | |
| Issuance costs in accounts payable and accrued expenses | 203,000 | 0 | 12,000 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Camp4 Therapeutics Corp's CIK number?
Camp4 Therapeutics Corp's SEC CIK number is 0001736730 (1736730). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Camp4 Therapeutics Corp's SEC filings?
All of Camp4 Therapeutics Corp's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Camp4 Therapeutics Corp last report earnings?
Camp4 Therapeutics Corp (CAMP) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001628280-26-032096). This is Camp4 Therapeutics Corp's most recent earnings filing of record — not a forecast of its next earnings date.
What is Camp4 Therapeutics Corp's most recent earnings 8-K?
Camp4 Therapeutics Corp's latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001628280-26-032096. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Camp4 Therapeutics Corp's latest earnings 8-K →
Look up any company's CIK number →